Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Agius

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Annals of the New York Academy of Sciences|December 21, 2012
Animal models of antimuscle-specific kinase myastheniaDavid P Richman, Kayoko Nishi, Michael J Ferns, et al.
Journal of Neuroimmunology|March 13, 2013
Genome wide differences of gene expression associated with HLA-DRB1 genotype in multiple sclerosis: a pilot studyMichelle L Apperson, Yingfang Tian, Boryana Stamova, et al.
Molecular Immunology|December 17, 2013
Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptorStuart W Morell, Vu B Trinh, Eswari Gudipati, et al.
Journal of Neuroimmunology|October 6, 2010
Differences in exon expression and alternatively spliced genes in blood of multiple sclerosis compared to healthy control subjectsYingfang Tian, Michelle L Apperson, Bradley P Ander, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 17, 2017
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose studyMark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, et al.
Annals of the New York Academy of Sciences|November 1, 2003
Agonist-induced transitions of the acetylcholine receptorRobert H Fairclough, Mark A Agius, Eswari Gudipati, et al.
Archives of Neurology|December 14, 2011
Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changesDavid P Richman, Kayoko Nishi, Stuart W Morell, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and managementAdam Cuker, Ann D Bass, Congor Nadj, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Annals of the New York Academy of Sciences|December 21, 2012
Animal models of antimuscle-specific kinase myastheniaDavid P Richman, Kayoko Nishi, Michael J Ferns, et al.
Journal of Neuroimmunology|March 13, 2013
Genome wide differences of gene expression associated with HLA-DRB1 genotype in multiple sclerosis: a pilot studyMichelle L Apperson, Yingfang Tian, Boryana Stamova, et al.
Molecular Immunology|December 17, 2013
Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptorStuart W Morell, Vu B Trinh, Eswari Gudipati, et al.
Journal of Neuroimmunology|October 6, 2010
Differences in exon expression and alternatively spliced genes in blood of multiple sclerosis compared to healthy control subjectsYingfang Tian, Michelle L Apperson, Bradley P Ander, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 17, 2017
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose studyMark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, et al.
Annals of the New York Academy of Sciences|November 1, 2003
Agonist-induced transitions of the acetylcholine receptorRobert H Fairclough, Mark A Agius, Eswari Gudipati, et al.
Archives of Neurology|December 14, 2011
Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changesDavid P Richman, Kayoko Nishi, Stuart W Morell, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2019
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and managementAdam Cuker, Ann D Bass, Congor Nadj, et al.
Pageof 2